# DESCRIPTION

## GRANT STATEMENT

- acknowledge government support

## TECHNICAL FIELD

- define technical field of diagnostics and therapeutics

## BACKGROUND

- introduce immune system response to cancer
- discuss tumor-specific CTL response
- describe colorectal cancer
- explain MHC-peptide complex recognition
- discuss antigen processing and presentation

## SUMMARY

- list embodiments of the presently disclosed subject matter
- describe compositions comprising synthetic target peptides
- detail modifications to target peptides
- describe compositions with adjuvants
- relate to in vitro populations of dendritic cells and CD8+ T cells
- describe antibodies or antibody-like molecules
- relate to methods for treating and/or preventing cancer
- describe methods for making a cancer vaccine
- relate to kits and methods for inducing a target peptide-specific memory T cell response

## BRIEF DESCRIPTION OF TABLES 3-9

- describe tables listing exemplary peptides and their characteristics

## DETAILED DESCRIPTION

- define terms and conventions

### I. Target Peptides

- introduce target peptides
- describe post-translational modifications
- specify peptide lengths and phosphorylation
- discuss modifications to enhance immunogenicity
- describe linkers and concatamers
- discuss anchor residues and MHC binding

### II. Phosphopeptides

- define phosphopeptides and MHC class I/II specificity
- describe phosphopeptide mimetics and examples

### III. Immunosuitablity

- define immunologically suitable peptides

### IV. Compositions

- define target peptide compositions
- describe composition components
- specify purity requirements
- discuss administration methods
- introduce selection criteria for target peptides
- describe target peptide vaccines
- outline treatment response rates
- describe compositions
- describe adoptive cell transfer
- describe additional peptides
- describe tumor-specific peptides
- outline combination therapies
- list therapeutic agents
- discuss T cell potentiators
- describe cytokine co-administration

### V. Types of Proliferative Diseases

- list proliferative diseases
- specify cancer types

### VI. Administration of Vaccine Compositions

- describe routes of administration
- formulate vaccine compositions
- provide adjuvants and their properties
- discuss pharmaceutical salts and framework formers
- list excipients
- specify pH ranges
- determine dosage
- describe administration schedule
- describe vaccine composition administration
- outline kit components and storage
- specify kit instructions and reconstitution
- detail markers for efficacy and immunological response
- describe assays for evaluating immune response

### VII. Antibodies and Antibody-Like Molecules

- introduce antibodies and antibody-like molecules
- define antibody, antibody peptide, and antibody-like molecule
- describe antibody fragments
- explain epitope and antibody binding
- discuss T cell receptor mimicry
- describe immunogen formation and antibody production
- define isolated antibody
- introduce antibody mutant and variant
- explain variable domain and complementarity determining regions
- describe antibody classes and subclasses
- introduce monoclonal antibody and humanization
- discuss fully human monoclonal antibodies
- introduce transgenic non-human animals for producing human antibodies
- describe method for producing non-human animal lacking endogenous immunoglobulin heavy chain
- outline method for producing antibody of interest using expression vectors
- discuss use of antibodies and antibody-like molecules in treating and diagnosing cancer
- describe detection of target peptides in biological samples using immunoassays
- explain recognition of antigens by T cells and use of synthetic peptides to stimulate T cell response
- outline preparation of kits for diagnosis, monitoring, and prognosis of diseases
- describe conjugation of antibodies or antibody-like molecules to therapeutic agents
- discuss use of target peptides in immunotherapy, including identification and selection of target peptides

## EXAMPLES

- provide illustrative embodiments

### Example 1

- identify MHC class-I-associated phosphopeptides associated with CRC

### Example 2

- assess healthy donor PBMC responses to CRC tumor-specific phosphopeptides

### Example 3

- establish phosphopeptide-specific T cell lines and assay for ability to kill CRC cell line

### Example 4

- describe T cell recognition and memory response assays

### Example 5

- isolate and characterize phosphopeptides from CRC tumor samples

